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(left to right).1332 The Journal of Thoracic and CardObjective: This study hypothesized that non–small cell lung carcinoma cells
from primary tumors isolated by laser capture microdissection would exhibit
gene expression profiles associated with graded lymph node metastatic cell
burden.
Methods: Non–small cell lung carcinoma tumors (n  15) were classified on
the basis of nodal metastatic cell burden by 2 methods, obtaining 3 groups: no
metastasis, micrometastasis, and overt metastasis. We then performed microar-
ray analysis on microdissected primary tumor cells and identified gene expres-
sion profiles associated with graded nodal tumor burden using a correlation-
based selection algorithm coupled with cross-validation analysis. Hierarchical
clustering showed the regrouping of tumor specimens; the classification infer-
ence was assessed with Fisher’s exact test. We verified data for certain genes
by using another independent assay.
Results: The 15 specimens clustered into 3 groups: cluster A predominated in
specimens with overt nodal metastasis; cluster B had more specimens with nodal
micrometastases; and cluster C included only specimens without nodal metastases.
Cluster assignment was based on a validated 75-gene discriminatory subset. Nota-
bly, genes not previously associated with positive non–small cell lung carcinoma
lymph node status were encountered in the profiling analysis.
Conclusions: Microdissection, combined with microarray analysis, is a potentially
powerful method to characterize the molecular profile of tumor cells. The 75-gene
expression profiles representative of clusters A and B may define genotypes prone
to metastasize. Overall, the 3 groups of tumor specimens clustered separately,
suggesting that this approach may identify graded metastatic propensity. Further,
genes singled out in clustering may yield insights into underlying metastatic mech-
anisms and may represent new therapeutic targets.
Lung cancer remains the most common cause of cancer-related mor-tality in North America, accounting for 30% of all cancer deaths,exceeding the next 4 cancers (breast, colon, prostate, and pancreas)combined.1 A critical, independent factor affecting the negativeprognosis of patients with non–small cell lung carcinoma (NSCLC)is lymph node metastasis, a process with poorly defined molecular
mechanisms. Nevertheless, the 5-year survival rate for patients with stage I lymph
node–negative NSCLC is only 39% to 67%.2 The relatively high mortality rate of
patients with stage I NSCLC is at least in part attributable to metastasis, often occult
at the time of initial diagnosis. Occult metastatic tumor cells or micrometastases,
routinely missed on histopathologic analysis, require immunohistochemical analysis
or polymerase chain reaction (PCR)based assays for detection. One study showedCunhathat the presence of such micrometastases in regional lymph nodes of patients with
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reduced disease-free interval.3 In other solid tumor types,
lymph node micrometastases correlated with primary tumor
depth of penetration, lymphatic vessel invasion, micro-
scopic venous invasion, and histologic stage.4,5 Taken to-
gether, this increasing body of evidence suggests that the
presence of micrometastases in NSCLC lymph nodes is
associated with a more biologically aggressive primary tu-
mor.3,6 Currently, the basis of this important association is
not well understood.
One investigative approach would be to identify molec-
ular characteristics from the primary resected tumor that
could predict the degree of lymph node micrometastatic cell
burden. Doing so would be advantageous, potentially obvi-
ating the cumbersome logistics of lymph node sampling and
of micrometastases detection. Microarray gene expression
profiling is uniquely suited for molecular characterization:
large numbers of genes can be simultaneously investigated,
and the resulting gene expression patterns can then be
correlated with certain clinical parameters.7 Using microar-
ray technology to analyze lung carcinoma tissue, research-
ers have identified subgroups of tumors differentiated ac-
cording to tumor type and histologic subclasses.8 Beer and
colleagues9 extended this body of work by demonstrating
that microarray gene expression profiles derived from tumor
tissue could predict overall survival in patients with early-
stage lung adenocarcinomas. Complementary to this ability
is the need to identify patients at high risk for recurrent or
metastatic disease. Recently, Kikuchi and coworkers10 re-
ported on the feasibility of using gene expression profiling
to predict gross, pathologic lymph node status in a subgroup
of patients with NSCLC adenocarcinomas.
Because the cellular heterogeneity of whole tumor spec-
imens may confound microarray analysis, we employed
laser capture microdissection (LCM)11 to isolate pure cell
populations for our molecular studies. Others have con-
cluded that the gene expression signature derived from pure
populations of tumor cells yields more precise, biologically
meaningful information on specimens of interest.10,12 Thus,
we hypothesized that pure populations of NSCLC cells
would exhibit a gene expression pattern associated with the
presence of not only overt metastatic cells but also, in
particular, micrometastases in lymph nodes. This specific
interest led us to select tumors with nodal micrometastases
to be contrasted against 2 extremes: tumors without evi-
dence (pathologic and molecular) of nodal involvement
versus advanced-stage tumors. We isolated tumor cells from
these 3 groups of tumors with graded lymph node metastatic
cell burdens for subsequent gene expression profiling. In
addition to analyzing the resulting gene expression patterns,
we also investigated individual component genes for poten-
tial insights into novel metastatic mechanisms.
The Journal of ThoracicMaterials and Methods
Patients and Tumor Specimens
All tumors and lymph nodes used in this study were obtained from
a tumor tissue bank at our institution. Clinical outcome results
from specimens used in this study were known only after all
microarray experiments were performed and analyzed. Surgically
resected specimens were collected under approval from the Insti-
tutional Review Boards at the University of Minnesota and the
Minneapolis Veterans Affairs Medical Center. Patients gave writ-
ten informed consent to have their tissues stored in a tumor tissue
bank beforehand. None of the patients had a history of lung cancer
or a concurrent malignancy, nor had they been exposed to any
chemoradiotherapy. All lymph node specimens were bivalved: half
were reserved for routine histopathologic analysis, and half were
immediately snap-frozen in liquid nitrogen. Histopathologic test-
ing verified that all surgical tumor specimens contained malignant
cells. From stage I patients, only lymph nodes confirmed as patho-
logically negative (N0) were used. Some patients were upstaged to
stage IIIa after histopathologic testing; they were also identified for
our study. Based on previous protocols,10,13 we used pooled,
noncancerous, male adult human lung total RNA isolated and
purified from tissue (Stratagene, La Jolla, Calif) as a reference
“normal” sample for each microarray experiment.
Determination of Lymph Node Micrometastatic Cell
Burden
Our group previously described in detail a carcinoembryonic
(CEA)-based real-time reverse transcriptase-PCR (QRT-PCR) as-
say to quantitatively estimate lymph node micrometastatic cell
burden.14 A lymph node station was considered positive by QRT-
PCR for CEA if it had 1000 micrometastatic cells (sensitivity of
the assay). Hematoxylin and eosin (H&E) status of lymph nodes
was determined by surgical pathologic analysis according to stan-
dard criteria. With each method, we identified results as positive
() or negative (). Patients with 5-year follow-up were identified
from our tissue bank, and their lymph nodes were tested until we
reached the following tumor specimen numbers: 5 H&E/(QRT-
PCR); 5 H&E/(QRT-PCR) (micrometastases); and 5
H&E.
Laser Capture Microdissection and RNA Processing
Tumor specimen sections were prepared by standard pathologic
techniques, then stained with H&E just before microdissection.
The PixCell II LCM System (Arcturus Engineering, Mountain
View, Calif) was used according to the manufacturer’s protocols.
A board-certified surgical pathologist (S.H.T.) assisted in the dif-
ferentiation of malignant cells. Areas of tumor necrosis were
identified and excluded from harvesting. In all, 3000 to 5000 cells
were laser captured for experiments. Total RNA was extracted
from LCM tumor samples using the PicoPure RNA isolation kit
(Arcturus Engineering), as outlined by the manufacturer. Adequate
RNA starting material was generated using a T7 RNA polymerase-
catalyzed linear amplification method.15 The RiboAmp RNA am-
plification kit (Arcturus Engineering) was used in 2 successive
rounds on all LCM-isolated RNA samples, as outlined by the
manufacturer. RNA purity was determined by spectrophotometry,
and integrity was verified on ethidium bromide-stained 2% agar-
ose-formaldehyde gels. To avoid any potential cDNA labeling bias
and Cardiovascular Surgery ● Volume 127, Number 5 1333
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nant lung total RNA in an identical manner.
cDNA Microarrays
Microarray experiments were performed, with minor modifica-
tions, using the MicroMax Human 2400-gene cDNA Microarray
System 1.1-TSA (Perkin Elmer LifeSciences, Boston, Mass).
Briefly, for every microarray, 1 g of amplified RNA from each
LCM tumor sample and the nonmalignant lung reference sample
was reverse-transcribed to target cDNA by adding 280 pmol
random hexamers (Promega, Madison, Wis) to the synthesis reac-
tion. We calculated the mean coefficient of variation (CV) among
microarray experiments (n  3) at 31%, suggesting adequate
reproducibility (and consistent with the manufacturer’s parame-
ters).
Microarray Analysis
Each gene was represented on a microarray in duplicate, so that a
corresponding raw expression ratio was defined as the mean signal
intensity of tumor sample:reference sample replicates (2 SD).
The raw expression ratios for each gene were median-centered
normalized16 to facilitate comparison of relative gene expression
levels. To identify a set of genes that could distinguish between
tumor samples on the basis of lymph node tumor burden, we
applied the separate groups, K-ordered groups filtering algorithm
(Expressionist v3.1, GeneData, San Francisco, Calif) to our entire
data set. This algorithm consists of combining rank-ordering tests
with a Pearson correlation coefficient to identify certain genes with
expression ratios that are consistent within and distinct between
defined groups. We selected a Pearson coefficient of 0.9 and
specified 3 groups according to our criteria for lymph node status.
This process identified a subset of genes that could be used to
classify the tumor cell samples into 3 separate groups of nodal
tumor burden. To determine the accuracy of our selection algo-
rithm in finding a discriminatory gene subset, we performed a
leave-one-out cross-validation analysis9 and calculated the error
rate. After validating the gene subset, we used it in 2-dimensional
hierarchical cluster analysis17 to visualize the subsequent cluster-
ing of tumor samples.
In another approach, we also selected genes that were greatly
overexpressed or underexpressed by tumor cells in comparison
with nonmalignant lung tissue by using a published filtering algo-
rithm,13 with modifications. Briefly, the 50th percentile of all
measurements per tumor sample was used as a positive control for
each gene; the signal intensity of every gene was divided by this
synthetic positive control. The bottom 10th percentile of measure-
ments was used as a test for background subtraction. The mea-
surement for each gene was then divided by the corresponding
signal intensity of the nonmalignant lung sample. The threshold
value used to define significant relative expression changes was set
at 3.0 for overexpression and 0.30 for underexpression on the basis
of the experimental variability in our data (CV  31%) and of the
manufacturer’s established performance criteria. Data filtering
with this algorithm identified genes overexpressed by at least
threefold and underexpressed by at least 30% across all specimens
and within subgroups.1334 The Journal of Thoracic and Cardiovascular Surgery ● MaQRT-PCR
To examine the reliability of our microarray data, we selected 3
overexpressed genes (pescadillo, Brk, OB-cadherin) and deter-
mined their relative expression in similar samples used for mi-
croarray analysis by QRT-PCR, according to our previous proto-
col.14 For each gene, as well as for an endogenous control gene
-glucuronidase (GUSB), we designed TaqMan probe and primer
sets from the open reading frame by using Primer Express software
v2.0 (Applied Biosystems, Foster City, Calif). Details of primer-
probe sequences are included in Appendix 1. PCR products of the
expected size for each gene were eluted from ethidium bromide-
stained 2% agarose gels; their identities were confirmed by se-
quence analysis.
Relative quantitation of gene transcripts was calculated by the
comparative threshold cycle method.18 GUSB was used as an
endogenous control for the normalization of sample loading be-
cause levels are consistent across diseased and nondiseased lung
tissues.19 The calibrator was chosen to be the same reference
sample (nonmalignant lung) used for microarrays to facilitate
comparison between the different techniques. Relative, normalized
quantitative gene expression levels were calculated for the 3 genes
of interest among tumor specimens.
Statistics
Microarray analysis was performed on Expressionist Suite v3.1
software (GeneData). The separate groups, K-ordered groups test
proceeded in 4 steps: transforming expression ratios to ranks,
rank-ordering within defined groups, rank-ordering between
groups, and calculating a Pearson correlation statistic. The leave-
one-out cross-validation analysis determined the robustness of the
classification method. A sample was withheld from the total num-
ber of tumor samples; the remaining samples were used to select a
set of discriminatory genes, and class prediction was made on the
withheld sample. This process was repeated for every sample so
that a cumulative error rate could be calculated. Fisher’s exact test
was used to assess whether or not cluster membership was asso-
ciated with physical and molecular characteristics of the tumor
samples.
Additional analysis was performed on S-Plus 6.1 software
(Insightful, Seattle, Wash). Kaplan-Meier curves were used to
estimate cause-specific patient survival (time in months from sur-
gery until death), as well as recurrence rates. The log-rank test was
used to assess differences among clusters. Differences of gene
expression results between microarray and QRT-PCR techniques
were analyzed according to previously described methods.20
Briefly, the distribution of log-transformed expression ratios (tu-




Characteristics of tumor specimens included in our analysis
are detailed in Table 1. In all, 10 NSCLC tumor specimens
were pathologic stage I (7 T1 N0 and 3 T2 N0) and 5 were
stage IIIa (2 T1 N2 and 3 T2 N2). By histologic examina-
tion, 12 specimens were adenocarcinomas; 3 were squa-
mous cell carcinomas. We considered that this mixture of
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representative of NSCLC nodal metastasis overall because
it is unknown whether or not different NSCLC types me-
tastasize via unique mechanisms (and genes).
We tested lymph nodes (4 to 7 nodes per tumor; 1 lymph
node per station) from the 10 stage I specimens to quanti-
tatively estimate micrometastatic cell burden. A total of 53
lymph nodes were analyzed, 14 (26%) of which were pos-
itive for CEA mRNA per our previous criteria (see Meth-
ods). These 14 lymph nodes were distributed among 5 of 10
stage I tumor specimens: 2 positive lymph nodes each in
specimens P8-9, 3 positive lymph nodes each in specimens
P1 and P10, and 4 positive lymph nodes in specimen P2. An
estimate of lymph node micrometastatic cell burden within this
5-tumor specimen group averaged 4.0  104  2.3  104
(SD) CEA-positive cells per lymph node station. This process
subdivided the stage I tumor specimens into 2 groups: 5
H&E/(QRT-PCR) and 5 H&E/(QRT-PCR). To en-
sure that these QRT-PCR results were valid, we tested both the
primary tumors (n  15) and H&E lymph nodes (n  9)
from the stage III tumor specimens. Correspondingly high
CEA-positive cell numbers were observed in 12 (80%) pri-
mary tumors and in 8 (89%) lymph nodes.
Hierarchical Cluster Analysis
On average, 300 to 500 genes were excluded from down-
stream analysis, per the previously discussed criteria, after
data normalization across these microarrays. The separate
groups, K-ordered groups test was performed with an average
of 2000 remaining genes from each microarray experiment per
TABLE 1. Molecular and pathologic characteristics of
NSCLC tumors
Specimens Histology T status Lymph node status
P1 AdenoCa T1 H&E/(QRT-PCR)
P2 AdenoCa T1 H&E/(QRT-PCR)
P3 AdenoCa T1 H&E/(QRT-PCR)
P4 AdenoCa T1 H&E
P5 SQ T2 H&E
P6 AdenoCa T1 H&E
P7 SQ T2 H&E
P8 AdenoCa T2 H&E/(QRT-PCR)
P9 AdenoCa T1 H&E/(QRT-PCR)
P10 AdenoCa T2 H&E/(QRT-PCR)
P11 AdenoCa T1 H&E/(QRT-PCR)
P12 AdenoCa T2 H&E
P13 AdenoCa T1 H&E/(QRT-PCR)
P14 AdenoCa T1 H&E/(QRT-PCR)
P15 SQ T2 H&E/(QRT-PCR)
NSCLC, Non–small cell lung carcinoma; AdenoCa, adenocarcinoma; SQ,
squamous; T, according to International TNM staging system; H&E, hema-
toxylin and eosin; QRT-PCR, real-time reverse transcriptasepolymerase
chain reaction.
Specimens P1 to P15 correspond to Figure 1.the 3 tumor groups defined above. This analysis identified a
The Journal of Thoracicsubset of 75 genes with significant differential expression
patterns between the 3 defined tumor groups (Appendix 2). In
other words, these genes displayed marked expression value
changes from 1 tumor group to another, thereby facilitating
tumor class discrimination. We coupled this gene-filtering
method with a cross-validation analysis, calculating an error
rate of 7%. The members of this 75-gene subset were diverse
and encoded for molecules with various functions such as
signal transduction, cellular structural components, transcrip-
tion factors, cellular growth, adhesion, and trafficking.
We employed this validated 75-gene subset in 2-dimen-
sional hierarchical clustering (Figure 1, A). We could not
identify a clear pattern of segregation in the clustering when
we examined each tumor by T status and histologic features
(P  .05) as expected (Table 1). However, cluster analysis
discriminated between tumor specimens according to
graded lymph node metastatic cell burden. Three distinct
tumor clusters were identified: cluster A predominated in
tumor specimens with H&E lymph nodes; cluster B had
more specimens with lymph node micrometastases; and
cluster C had only specimens without any lymph node
metastases (Figure 1, B). A significant association between
cluster membership and the 3 groups of lymph node tumor
burden was not discernible (P .13), but this result was not
entirely unexpected given the small sample size. Neverthe-
less, the P value trended in the appropriate direction toward
statistical significance, warranting the addition of more
study specimens. The number of tumor specimens with any
degree of nodal metastasis decreased in a graded fashion
across clusters A to C (Figure 1, B). The extent of lymph
node metastasis also varied among clusters, as expected.
Cluster A had a total of 14 tumor-positive lymph nodes [7
from stage III tumor specimens and 7 from H&E/(QRT-
PCR) specimens]; cluster B, an intermediate number: a
total of 9 tumor-positive lymph nodes [2 from a stage III
specimen and 7 from H&E/(QRT-PCR) specimens].
Cluster C was devoid of any nodal tumor involvement.
Clinical Data
Cause-specific 5-year survival (top) and NSCLC recurrence
(bottom) data for the 15 patients are detailed in Table 2. The
number of deaths secondary to NSCLC increased from
cluster C (no deaths) to cluster A (3 deaths). The number of
patients with NSCLC recurrence also increased from cluster
C to cluster A, whereas the median time to recurrence
decreased by more than half from cluster B to cluster A.
Kaplan-Meier curves reflected these trends (data not
shown), but P values did not reach statistical significance, as
expected with this small sample size.
Differentially Expressed NSCLC Genes
Genes with significant overexpression and underexpression in
common across tumor specimen groups were identified by
and Cardiovascular Surgery ● Volume 127, Number 5 1335
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mens with greater than threefold overexpression relative to the
Figure 1. Hierarchical cluster analysis. A, Two-dime
75-gene subset with differential expression across tum
accession numbers for all 75 genes are shown; specim
signal intensities for each gene. B, An enlarged view
summary table of tumor specimen lymph node status.reference, and conversely 45 genes with30% underexpression.
1336 The Journal of Thoracic and Cardiovascular Surgery ● MaSpecimen subgroup analysis identified genes as follows:
H&E/(QRT-PCR), 157 over- and 242 underexpressed;
nal hierarchical clustering of primary tumors per a
ecimen groups. Genes lie vertically and the GenBank
lie horizontally. Colors are mean, relative expression
e tumor specimen dendrogram from (A) along with ansio
or sp
ens
of thH&E/(QRT-PCR), 190 and 280; H&E, 150 and 200.
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were identified (Appendixes 2 and 3). The CL100 gene was
significantly underexpressed by an average of 0.087. Both
VAV2 (14.5-fold) and Brk (7.8-fold) were overexpressed in
the specimen group with nodal micrometastases and con-
versely had low expression levels in the other 2 specimen
groups. As the focus of our study was to identify gene
expression patterns associated with metastatic potential,
subgroup analysis of significantly altered genes in speci-
mens with nodal micrometastases may be revealing (Ap-
pendix 3). Relative overexpression in specimens of
OB-cadherin mRNA was 43.8-fold; of pescadillo mRNA,
39.5-fold. Concurrently, nidogen transcripts were underex-
pressed at 0.121 in specimens with nodal micrometastases.
Comparison of our results to previous NSCLC microar-
ray profiling studies showed qualitative similarity in certain
genes. Notable overexpressed or underexpressed genes in
common with the study by Heighway and colleagues21
included osteopontin, insulin-like growth factor binding
protein 2, gastrin-releasing peptide, and CL100; in common
with the study by Beer and coworkers,9 aldolase A, cathep-
sin, and protein tyrosine phosphatase; and in common with
the study by Bhattacharjee and colleagues,8 high-mobility
group protein and bullous pemphigoid antigen. General
agreement between different microarray studies using inde-
pendent lung carcinoma samples suggests that many of
these genes are likely relevant to NSCLC.
Verification of Microarray Data
Using QRT-PCR, we validated microarray expression data
for 3 overexpressed genes (Brk, pescadillo, and OB-cad-
herin). Overall, results for each gene were broadly consis-
tent between the 2 different techniques; for each gene tested,
the QRT-PCR–derived median expression ratio changed in
the same direction of differential expression as previously
identified by the microarray analysis. These data confirmed
the reliability of our microarray strategy in identifying dif-
ferentially expressed genes from tumor specimens with
varying nodal metastatic cell burden.
Discussion
Clustering algorithms have revealed subtle, specific patterns
of gene expression useful for molecular classification of
various cancers.8 Our study demonstrated the feasibility of
using expression profiling to differentiate for the presence
of lymph node micrometastases within stage I tumors. Our
work extends that of Kikuchi and colleagues10: we examined
the molecular profile of tumors with nodal micrometastases as
compared with advanced stage III tumors. The Kikuchi study
focused on microarray identification of overt nodal status in a
subset of adenocarcinomas, not reporting the specific clinico-
pathologic details of the patient group. Thus, in their study,
identifying expression profiles specific to early-stage NSCLC
The Journal of Thoracictumors (which are associated with a relatively poor patient
survival rate and high recurrence rate) was difficult. Gene
profiles of stage I NSCLC tumors associated with nodal mi-
crometastatic cell burden may identify a high-risk subgroup
prone to develop overt nodal metastases that could benefit from
more aggressive initial therapy.
In our study, hierarchical clustering segregated LCM
NSCLC specimens by graded lymph node metastatic burden
(per CEA QRT-PCR), according to a 75-gene subset. The
association, in the literature, of many of these subset genes
with the pathogenesis of various epithelial-derived cancers
lends indirect support for the validity of our 75-gene selec-
tion process. For example, VAV2, a signal transduction
gene, is associated with ovarian tumor progression.22 And
Brk, a signaling transduction nonreceptor protein tyrosine
kinase, is capable of potentiating the mitogenic response to
epidermal growth factor in mammary epithelial cells23 and
is overexpressed only in metastatic melanoma subtypes.24
Both VAV2 and Brk were overexpressed in our group of
tumor specimens with nodal micrometastases; thus, they
may be potential tumor markers of early metastases.
In general, the 75-gene signature of cluster A may define
a poor prognosis expression profile as cluster A contained
mostly stage III tumor specimens. Also, we noted 1 H&E/
(QRT-PCR) tumor specimen (P3) that grouped into clus-
ter A because it displayed an expression profile more similar
to advanced-stage tumors. This observation proved to be
biologically relevant: records indicated that patient P3 suf-
fered a relapse at the initial resection site 7 months postop-
eratively, with a total survival time of only 11 months.
Conversely, the gene signature of cluster C may define a
subgroup of stage I lymph node–negative [H&E/(QRT-
PCR)] patients with a favorable prognosis. Further, it may
be significant that tumor specimens with lymph node mi-
crometastases were distributed between clusters A and B,
possibly consistent with the presence of novel micrometa-
static molecular subgroups. Distinct micrometastatic sub-












Cluster A 1 1 1 3 3
Cluster B 1 1 0 2 1





Cluster A 1 1 1 3 11
Cluster B 0 1 1 2 24.5
Cluster C 0 0 0 0 —groups may have significant implications for intermediate
and Cardiovascular Surgery ● Volume 127, Number 5 1337
General Thoracic Surgery Hoang et al
G
TSsurvival and cancer recurrence. Again, in our study, clinical
data supported our conclusions. Of patients with nodal
micrometastases, 2 of 3 (P8 and P10) in cluster B remain
alive and disease-free; however, 1 of 2 (P2) in cluster A
suffered a distant NSCLC relapse and survived only 15
months postoperatively.
We also identified significantly altered genes with poten-
tial functional links to NSCLC tumorigenesis (Appendixes
2 and 3). CL100, a homolog of mitogen-activated protein
kinase phosphatase 1, functions as a protein tyrosine phos-
phatase negatively regulating tyrosine kinase action.25 Loss
of this gene, as displayed in all 15 of our specimens, may
perpetuate tyrosine kinase–driven tumor growth, as evi-
denced in ovarian carcinoma cell lines.25 Among tumor
specimens with nodal micrometastases, we identified a
3-gene set suggesting unrecognized mechanisms involved
in NSCLC metastasis. OB-cadherin has been associated
with more aggressive variants of breast or gastric cancers in
which the gene product mediates formation of adherens
junction complexes, enhancing the invasive ability of can-
cer cells.26 Pescadillo has been shown to be overexpressed
in malignant astrocytes, colon, and breast carcinoma cell
lines; it regulates the cell cycle in a manner permissive for
tumor progression.27 Both of those genes were markedly
overexpressed in this tumor subgroup; presumably, these
have similar function. Interestingly, nidogen, a basement
membrane-stabilizing molecule,28 was significantly under-
expressed in this subgroup of tumors with nodal microme-
tastases. Intuitively, we believe that basement membrane
instability would be a prerequisite for metastasis. In a com-
parison with our other 2 tumor subgroups, we found a
similar gene expression profile of these 3 genes in stage III
tumors but not in stage I tumors with H&E/(QRT-PCR)
lymph nodes. This finding suggests that some early-stage
primary tumors with associated lymph node metastases may
behave aggressively because they share a gene profile sim-
ilar to advanced-stage primary tumors.
Admittedly, the sample sizes of our tumor specimen
groups were too small to make broad, definitive generali-
zations on the lymph node status of NSCLC tumors based on
the hierarchical cluster data. With a larger number of speci-
mens, we would anticipate a more distinct and statistically
significant delineation of cluster assignment correlating with
quantitative lymph node micrometastatic cell burden. None-
theless, our preliminary results support the concept of investi-
gating this approach further for large-scale profiling of primary
tumor cells to identify critical gene expression patterns.
Another limitation of our study was the use of different
types of starting RNA source material: LCM tumor cells
compared against pooled whole-lung tissue. Despite the
potential to introduce experimental bias, Kikuchi and co-
workers10 used the identical approach without obvious
problems. Additionally, testing the predictive ability of the
1338 The Journal of Thoracic and Cardiovascular Surgery ● Ma75-gene subset on additional specimens would be an im-
portant next step toward prospectively classifying tumors by
degree of lymph node metastatic cell burden. Currently, it is
unknown whether the gene expression profiles defining
tumor specimens in clusters A, B, and C have any prognos-
tic impact, but our limited findings suggest differential
survival among cluster groups.
In summary, LCM of primary tumors combined with
microarray analysis identified a 75-gene expression profile
that may identify early-stage NSCLC primary tumors that
have increased metastatic propensity. Our approach differ-
entiated between tumor specimens by graded levels of
lymph node metastatic burden, identifying specimens with
micrometastases separately from those with overt metasta-
ses. The individual genes defined by hierarchical clustering
may suggest contributing pathogenic mechanisms in
NSCLC and may represent new, early therapeutic targets. In
future studies, it will be critical to test the ability of our
75-gene subset to predict nodal micrometastases to identify
a subgroup of patients who may benefit from additional
therapy. To refine this concept, it will also be important to
correlate the primary tumor molecular signature with dif-
fering quantitative estimates of micrometastatic cell lymph
node burden, possibly revealing molecular subgroups of
tumors with micrometastases.
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APPENDIX 1: Sequences of TaqMan primers and
probes
Brk forward primer 5-CCATGACCACAATATCCCCTACA-3,
reverse 5-ACGTCGGATTTGGTGGAGTAA-3, and probe
5-TGGACGGCCCCTGAAGCGC-3; OB-cadherin forward
primer 5-AAGACATCAAACCTGAGTATCAGTACATG-3,
reverse 5-CATCGACATCCACGCTGTTG-3, and probe 5-
TAGACCTGGGCTCCGGCCAGC-3; pescadillo forward
primer 5-CCATTCATCCTGGCTTTCCA-3, reverse 5-CCTA-
CCCTCACCCCATCACA-3, and probe 5-CACAGTTGGAC-
CCGTGATTCTCAGGG-3; and GUSB forward primer
5-CTCGGCAGAGACAACCAAAAA-3, reverse 5-GGTT-
TCATTGGCAATCTTCCA-3, and probe 5-TGCAGCG-
TTCCTTTTGCGAGAGAGAT-3
See Appendix 2 on page 1340.and Cardiovascular Surgery ● Volume 127, Number 5 1339
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High-mobility group protein HMG Maintenance of nucleoprotein
complexes
Y10043 6.9 (21.9) 52.0 (201.5) 34.7 (147.5)
(clone hKvBeta3) K channel beta
subunit
Ion channel L39833 1.3 (1.6) 5.1 (10.3) 0.578 (1.2)
ZIP-kinase Serine/threonine kinase AB007144 6.7 (12.1) 29.5 (66.4) 2.4 (3.3)
VAV2, VAV oncogene homolog Cell signaling S76992 3.9 (6.4) 14.5 (35.3) 3.3 (5.9)
Neuronatin alpha Neural development U25033 7.2 (14.4) 29.1 (41.5) 2.0 (4.3)
mki67a (short type) for antigen of
monoclonal antibody Ki-67
Cell proliferation X65551 3.4 (3.1) 70.8 (154.4) 1.9 (1.0)
Casein kinase I epsilon DNA replication and repair L37043 2.9 (1.3) 9.9 (18.9) 4.4 (3.8)
Bullous pemphigoid antigen (BPAG1) Cytoskeletal protein L11690 2.6 (5.6) 8.2 (10.1) 4.5 (6.4)
5-HT6 serotonin receptor Serotonin signaling L41147 3.7 (12.5) 2.8 (5.9) 1.2 (2.3)
DNA-binding protein (SMBP2) Immunoglobulin class switching L14754 8.2 (21.7) 20.2 (30.1) 3.7 (5.9)
Transthyretin (Ttr) Hormone transport X59498 3.8 (3.8) 8.5 (8.9) 1.8 (1.8)
Villin-like protein Cytoskeletal protein D88154 2.1 (3.2) 30.6 (64.5) 4.8 (18.8)
Parathymosin Cell proliferation M24398 3.9 (5.7) 18.0 (27.2) 6.4 (14.9)
Gastrin-releasing peptide Autocrine growth factor K02054 1.4 (1.2) 0.729 (0.620) 11.8 (10.3)
Receptor-type protein tyrosine
phosphatase
Protein dephosphorylation L09247 3.8 (9.3) 2.9 (2.9) 1.0 (0.860)
Guanine nucleotide-binding regulatory
protein
Intracellular signaling M69013 6.7 (11.8) 10.2 (20.9) 2.0 (3.1)
Rhodanese (Rohu) Chaperone substrate X59434 3.7 (4.0) 8.8 (10.3) 1.5 (3.0)
DNA repair protein (XRCC1) DNA repair M36089 13.9 (11.5) 19.0 (5.1) 5.9 (12.9)
Atrophin-1 related protein Unknown AF001845 7.2 (15.3) 26.4 (14.4) 13.4 (19.2)
Brk mRNA for tyrosine kinase Protein phosphorylation,
intracellular signaling
cascade
X78549 2.2 (2.7) 7.8 (7.7) 1.8 (2.3)
cdc2-related protein kinase (CHED) Cell division regulation M80629 1.0 (0.860) 6.0 (8.3) 1.8 (2.8)
IgG Fc binding protein Immune regulation D84239 5.1 (3.6) 10.1 (10.8) 3.4 (3.8)
Alpha 2 delta calcium channel subunit Calcium homeostasis AF042793 1.1 (1.4) 10.7 (28.7) 1.7 (1.8)




AF034795 13.0 (27.7) 15.9 (22.3) 37.1 (111.9)
Pancreatitis-associated protein (PAP)
homologous protein
Pancreas stress protein D13510 2.3 (4.5) 3.3 (2.6) 2.4 (4.5)
PDCD2, programmed cell death-2
(Rp8 homolog)
Apoptosis regulation S78085 0.592 (0.680) 0.671 (0.446) 0.519 (0.557)




S66431 0.419 (0.409) 0.629 (0.435) 0.816 (0.508)
jun-B protein Oncogene X51345 2.7 (8.1) 0.335 (0.321) 0.462 (0.289)
Heat shock protein 40 Stress protein, chaperone D49547 0.012 (0.011) 0.005 (0.097) 0.032 (0.045)
P21 receptor Cell signaling U45448 7.3 (16.1) 0.905 (1.5) 3.0 (2.9)
GABA-A receptor, gamma 2 subunit Neurotransmission X15376 6.7 (16.4) 1.5 (1.6) 3.8 (8.3)
DNA mismatch repair protein homolog
(hMLH1)
DNA repair U07343 0.681 (0.831) 0.265 (0.103) 0.473 (0.362)
Squalene synthase Sterol biosynthesis X69141 0.096 (0.172) 0.123 (0.109) 0.311 (0.240)
Clone 24444 RaP2 interacting protein 8
(RP1P8)
GTP binding regulation AF055026 9.7 (16.7) 5.5 (9.4) 3.0 (7.1)
Octamer-binding protein, Oct-1 Transcription factor X13403 5.0 (11.8) 1.3 (1.3) 0.698 (0.872)
Prepro-alpha2(1) collagen Cytoskeletal protein Z74616 1.9 (3.6) 0.224 (0.343) 0.939 (2.0)
Nerve growth factor (HBNF-1) Neuronal growth M57399 2.7 (5.3) 1.0 (0.735) 0.318 (0.147)
RNA polymerase II associated protein,
RAP 74
Transcription initiation factor X64037 6.2 (8.4) 6.2 (9.9) 2.1 (3.3)
Chromatin assembly factor-1 p150
subunit
DNA replication U20979 5.0 (4.1) 6.3 (10.7) 2.5 (3.6)
mRNA for KIAA0161 gene Unknown D79983 3.8 (13.6) 0.820 (1.3) 0.228 (0.130)
ARP1 protein Transcription factor X91504 10.2 (11.7) 6.3 (8.4) 2.5 (2.1)
H&E, Hematoxylin and eosin; QRT-PCR, real-time reverse transcriptase-polymerase chain reaction.
Numerical data are mean, relative expression ratios (fold or fraction changes) without units (2 SD).1340 The Journal of Thoracic and Cardiovascular Surgery ● May 2004
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Epidermal growth factor receptor
substrate (eps15)
Cell growth regulation U07707 28.1 (56.3) 67.6 (96.1) 9.6 (10.3)
Glucose transporter (HepG2) Glucose metabolism K03195 156.5 (348.3) 19.3 (26.6) 47.5 (161.1)
Integrase interactor 1 (Ini 1) Nuclear factor U04847 38.0 (93.9) 53.5 (91.0) 19.3 (19.9)
Ninjurin1 (nerve injury—induced
protein)
Cell adhesion U72661 19.3 (34.7) 140.1 (483.6) 10.0 (9.7)
Cathepsin D Aspartic lysosomal proteinase M11233 31.1 (44.9) 18.1 (29.1) 22.9 (57.4)
Frataxin (FRDA) Mitochondrial iron metabolism U43747 12.2 (13.3) 17.0 (50.4) 6.3 (3.1)
msg1-related gene 1 (mrg1) Transcription factor U65093 17.9 (33.4) 51.2 (111.4) 25.6 (44.5)
Triadin Calcium homeostasis U18985 8.5 (10.1) 39.8 (46.6) 21.1 (55.8)
RGP3 G protein signaling U27655 14.4 (38.3) 26.9 (53.9) 13.1 (14.7)
mRNA for osteopontin Bone matrix protein X13694 113.2 (229.6) 81.8 (140.1) 75.3 (143.1)
Hepatocyte growth factor
activator inhibitor (HAI-1)
Protease inhibitor AB000095 167.3 (429.8)
OB-cadherin-1 (cadherin-11) Cellular adhesion D21254 43.8 (106.7)
Calnexin Protein trafficking L18887 13.1 (16.4)
Creatine transporter Protein transport, bioenergetics L31409 18.3 (31.9)
Insulin-like growth factor binding
protein-2 (IGFBP-2)
IGF binding protein M35410 1887.2 (8255.8)
Zinc finger protein (ZNF76) DNA binding protein M91592 17.9 (52.5)
p38 gamma MAP kinase Cell signaling U66243 35.0 (53.6)
Pescadillo Cell cycle regulation U78310 39.5 (45.4)
HPV16 E1 protein bind protein DNA replication U96131 30.9 (50.6)
Clone C-2k, cdc2-related Serine/threonine kinase X80230 12.6 (14.2)
CLPP Protease Z50853 23.4 (38.3)
Underexpressed genes
Gravin Kinase scaffold protein AB003476 0.039 (0.064) 0.031 (0.118) 0.049 (0.114)
Mitochondrial matrix protein P1 Chaperone, posttranslational
activity
M22382 0.004 (0.009) 0.004 (0.018) 0.008 (0.012)
Putative tumor suppressor ST13 Tumor suppressor U17714 0.060 (0.141) 0.046 (0.122) 0.057 (0.065)
Transforming growth factor beta-2 Growth factor, cell cycle
regulation
M19154 0.076 (0.169) 0.140 (0.232) 0.037 (0.122)
Cell adhesion protein receptor
alpha subunit (vitronectin)





M67509 0.039 (0.033) 0.030 (0.050) 0.060 (0.136)
Inhibitor of apoptosis protein 2 Apoptotic suppressor U45879 0.093 (0.095) 0.049 (0.034) 0.072 (0.040)
Syntaxin 7 Intracellular vesicle trafficking U77942 0.132 (0.132) 0.010 (0.151) 0.112 (0.237)




X68277 0.063 (0.106) 0.080 (0.215) 0.117 (0.248)
Nucleoporin-like protein Nucleocytoplasmic transport X89478 0.127 (0.156) 0.115 (0.158) 0.122 (0.115)
Garp Protein-protein interaction,
signal transduction
Z24680 0.111 (0.106) 0.117 (0.211) 0.086 (0.153)
Pig7 (PIG7) p53 target AF010312 0.092 (0.210)
Protocadherin 68 (PCH68) Cell adhesion AF029343 0.061 (0.116)
Ras-related GTP-binding protein Ras signal transduction D78132 0.058 (0.097)
Protein phosphatase 2A B56  Protein dephosphorylation L76703 0.127 (0.195)
Ras-related protein (Krev-1) Tumor suppressor M22995 0.015 (0.025)
Nidogen Basement membrane component M30269 0.121 (0.220)
Mutated in multiple advanced
cancers (MMAC) protein
Tumor suppressor U92436 0.037 (0.128)
Novel DNA binding protein Transcriptional regulation X63071 0.062 (0.079)
Translin Consensus sequence binding X78627 0.092 (0.075)
mRNA for hevin-like protein Extracellular matrix, cell adhesion X86693 0.004 (0.098)
Caveolin Caveolae structural protein,
candidate tumor suppressor
Z18951 0.031 (0.080)
H&E, Hematoxylin and eosin; QRT-PCR, real-time reverse transcriptase-polymerase chain reaction.
Numerical data are mean, relative expression ratios (fold or fraction changes) without units (2 SD).The Journal of Thoracic and Cardiovascular Surgery ● Volume 127, Number 5 1341
General Thoracic Surgery Hoang et al
G
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Dr Bryan Meyers (St Louis, Mo). Those are very elegant exper-
iments and certainly a good step in the right direction with your
preliminary work. I would ask you to discuss a little bit about the
findings between 2 different clusters, cluster A being the tumors
that were T2 and cluster B, the tumors that were T1. One of the
challenges with a small number of tumors like this, particularly
when they are heterogenous, is that you are drawing some con-
clusions based on your molecular findings, but there are some
other macroscopic findings that are also very associated with the
tendency toward lymph node metastases.
Dr Hoang. Thank you for your comments. For clarification,
cluster A was not comprised solely of T1 tumors nor was cluster
B comprised solely of T2 tumors. The hierarchical clustering was
based on a subset of genes that differentiated between tumor
specimens by graded lymph node tumor burden. The resulting
segregation of specimens into separate groups was therefore de-
termined by nodal status. To ensure that this was the case, we
examined the distribution of specimens according to other physical
and molecular characteristics, including T status. There were no
statistically significant associations, except for nodal status.
Dr Thomas A. D’Amico (Durham, NC). Dr Hoang, that was a
wonderful presentation. I admire your work, and you and your
colleagues should be congratulated. I wonder if you could discuss
why you chose the presence of lymph node micrometastasis as the
parameter to distinguish prognostic potential among stage I pa-
tients. There are other molecular markers, antigens, proteins, or
gene mutations that would have given you a wider scope of tumors
to choose from to use this 75-gene discriminant analysis to look at
subgroups. Limiting yourself to whether or not a micrometastasis
is present maybe wouldn’t give you the same latitude. Could you
discuss why you chose those subgroups?
Dr Hoang. Thank you for your very insightful question. A
main focus of our lab is centered on mechanisms of nodal metas-
tasis in NSCLC. Because micrometastases represent an early form
of tumor dissemination, a better understanding of their biology
may lead to new insights into underlying mechanisms. This spe-
cific interest led us to select tumors with nodal micrometastases for
comparison against a true negative, that is, no nodal metastases
(determined by H&E and by our CEA QRT-PCR assay) versus a
true positive, that is, overt nodal metastasis (advanced-stage tu-
mors).
Dr Larry R. Kaiser (Philadelphia, Pa). Your 2400-gene array
is a fairly small array. Was this somehow selected prior to using it?
Dr Hoang. This 2400-gene cDNA microarray was a commer-
cial resource readily available to our laboratory. The 2400 genes
spotted on the microarray represent a broad cross section of gene
functional categories (eg, transcription factors, cell regulatory fac-
tors, cell signaling, cell adhesion, and so on), making it well suited
for the broad gene profiling approach we used. Thus, there was no
predetermined selection process.
Dr Kaiser. And most genomics data is not particularly useful
unless it is validated externally. Did you attempt to validate this
externally, for instance, with the data from Beer or from Bhatta-
1342 The Journal of Thoracic and Cardiovascular Surgery ● Macharjee, which was the paper from the Proceedings of the National
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Dr Hoang. That is an excellent question and important point
you raise about microarray studies in general. With respect to your
specific question about direct comparison of our data to the public
lung cancer databases at Michigan (Beer and colleagues) and
Harvard (Bhattacharjee and colleagues), we have not done that.
There are significant technical reasons for not doing so that en-
compass differences in: (1) microarray platform (oligonucleotide
vs cDNA), in number of overlapping genes present on each array,
(2) specific types of samples being compared (whole tissue vs
cells), (3) the reference sample (pooled tissue, pooled cell lines,
single samples, tumor vs normal in same patient, etc), (4) normal-
ization protocol, and (5) lack of consensus on a uniform approach
to compare data across different studies. Thus, we are not sure of
what approach would be taken or how valid it would be to attempt
such a direct comparison. A crude method could consist of qual-
itative comparisons of genes reported as overexpressed or under-
expressed.
Dr Kaiser. Another thing is that the statistical validation of any
of these is particularly important, and we didn’t hear much in the
way of any statistical validation of any of these results. For
instance, you had osteopontin as 90-fold up-regulated. Was that
just due to 1 sample, was it a low expressor, what was the P value?
There was some of the data that was a little bit hard to believe in
terms of how much some of the gene expression was up-regulated.
Dr Hoang. Again, you bring up another important point about
microarray data analysis. This is a rapidly evolving field with a
multitude of statistical approaches, all of which have certain ad-
vantages and disadvantages. Currently there is no consensus on
what the best approach is or if there should be a uniform approach
taken. The K groups analysis we used refers to a family of
data-filtering algorithms (part of our array analysis software); the
specific test we performed to identify our discriminatory 75-gene
subset is the separate groups, K groups test. This selection algo-
rithm relies on a combination of rank-ordering tests with a Pearson
correlation coefficient. The end result of applying this algorithm is
the identification of genes with maximal variation between defined
groups (3 in this case) that could be used to classify samples.
Depending on a number of technical factors (such as microar-
ray platform, normalization algorithm, and type of comparison
between experimental vs reference samples), a relatively large
range of expression values could result. With respect to osteopon-
tin, all 15 of our tumor specimens showed elevated expression with
a range of about 6-fold to 260-fold. We did not report a P value
because our gene selection process relied on a correlation-based
statistic.
Dr Kaiser. I think it is safe to say it is very interesting, but
without some external validation, we have to be very careful about
looking at genomics data.
Dr Hoang. We agree with your cautionary stance, overall. To
address this concern, we used real-time PCR (the most common
validation technique in current usage) to externally validate our
microarray data for certain genes of interest. Overall, the 2 inde-
pendent methods showed qualitative agreement.
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